Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

9 treatments under study, led by Warfarin

Research Leaders

10 sponsors active, led by Drug Safety and Effectiveness Network, Canada

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 8 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 3 (1)
Phase 4 (2)

Trial Status

Completed4
Recruiting2
Active Not Recruiting1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05995600Phase 4Active Not Recruiting

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE

NCT03862859Phase 4Recruiting

The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis

NCT05679024Phase 3Recruiting

Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

NCT03596502Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)

NCT05337202Unknown

the Dutch-GERAF Study

NCT05195372Completed

Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome

NCT03568916Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

NCT02833987Completed

Direct Oral Anticoagulants and Venous Thromboembolism

Showing all 8 trials

Research Network

Common Treatments

  • Warfarin3
  • Apixaban Atc B01af022
  • Rivaroxaban Atc B01af012
  • Dabigatran Atc B01ae072
  • Warfarin Atc B01aa031

Active Sponsors

  • Drug Safety and Effectiveness Network, Canada3
  • Canadian Institutes of Health Research (CIHR)3
  • Canadian Network for Observational Drug Effect Studies, CNODES3
  • Samjin Pharmaceutical Co., Ltd.1
  • Seoul National University Hospital1

Top Investigators

Related Conditions

  • Atrial Fibrillation4
  • Ischemic Stroke3
  • Stroke2
  • Systemic Embolization2
  • Myocardial Infarction2

Activity Timeline